Bayer AG’s new chief executive said he’s weighing a breakup of the pharma and agriculture conglomerate, a move that could undo much of the legacy of his predecessor, including the troubled acquisition of Monsanto.
To read the entire story, you must be logged in.
Please log in now or register with us.
